P-45 An open-label, phase 2 study of patritumab deruxtecan in patients with previously treated advanced/metastatic colorectal cancer

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30272-4 ◽

2019 ◽

Vol 20 (8) ◽

pp. 1070-1082 ◽

Cited By ~ 43

Author(s):

Tanios S Bekaii-Saab ◽

Fang-Shu Ou ◽

Daniel H Ahn ◽

Patrick M Boland ◽

Kristen K Ciombor ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Dose Optimisation ◽

Open Label Phase

PD-1 MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)

Annals of Oncology ◽

10.1016/j.annonc.2021.05.019 ◽

2021 ◽

Vol 32 ◽

pp. S199

Author(s):

S. Siena ◽

E. Elez ◽

M. Peeters ◽

T. André ◽

M. Van den Eynde ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028323.793480222 ◽

2013 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Metastatic Soft Tissue Sarcoma ◽

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(20)30109-1 ◽

2020 ◽

Vol 21 (5) ◽

pp. 671-684 ◽

Cited By ~ 68

Author(s):

Ghassan K Abou-Alfa ◽

Vaibhav Sahai ◽

Antoine Hollebecque ◽

Gina Vaccaro ◽

Davide Melisi ◽

...

Keyword(s):

Locally Advanced ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(19)30041-x ◽

2019 ◽

Vol 4 (5) ◽

pp. 376-388 ◽

Cited By ~ 8

Author(s):

Stine Braendegaard Winther ◽

Gabor Liposits ◽

Halla Skuladottir ◽

Eva Hofsli ◽

Carl-Henrik Shah ◽

...

Keyword(s):

Colorectal Cancer ◽

Combination Chemotherapy ◽

Phase 2 ◽

Open Label ◽

Reduced Dose ◽

Phase 2 Trial ◽

Vulnerable Patients ◽

Open Label Phase ◽

Dose Combination

LBA-05 Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdv262.05 ◽

2015 ◽

Vol 26 ◽

pp. iv118 ◽

Cited By ~ 16

Author(s):

E. Van Cutsem ◽

F. Ciardiello ◽

J-F. Seitz ◽

R. Hofheinz ◽

U. Verma ◽

...

Keyword(s):

Colorectal Cancer ◽

Open Label ◽

Open Label Phase ◽

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-014-2391-2 ◽

2014 ◽

Vol 73 (4) ◽

pp. 695-702 ◽

Cited By ~ 16

Author(s):

Carlos R. Becerra ◽

Ramon Salazar ◽

Rocio Garcia-Carbonero ◽

Anne L. Thomas ◽

Federico J. Vázquez-Mazón ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Open Label ◽

Open Label Phase ◽

5-fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): An investigator-initiated, open-label, single-arm, multicentre, phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e15540 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e15540-e15540 ◽

Cited By ~ 1

Author(s):

Nicolas Isambert ◽

Alice Hervieu ◽

Audrey Hennequin ◽

Christophe Borg ◽

Cedric Rebe ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Study

STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps3652 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS3652-TPS3652

Author(s):

Johanna C. Bendell ◽

Benjamin R. Tan ◽

James Andrew Reeves ◽

Henry Q. Xiong ◽

Rita Laeufle ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase

PD-012 Analysis of patients ≥75 years in the open-label phase 3b CONSIGN trial of regorafenib in previously treated metastatic colorectal cancer (mCRC)

Annals of Oncology ◽

10.1093/annonc/mdw200.12 ◽

2016 ◽

Vol 27 ◽

pp. ii106 ◽

Cited By ~ 1

Author(s):

E. Van Cutsem ◽

F. Ciardiello ◽

M. Ychou ◽

J.-F. Seitz ◽

R. Hofheinz ◽

...

Keyword(s):

Colorectal Cancer ◽

Open Label ◽

Open Label Phase ◽